- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00153985
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
July 24, 2013 updated by: Catherine Wu, MD, Dana-Farber Cancer Institute
Multi-Center Study Using Allogeneic Stem Cell Transplantation Following Reduced Intensity Chemotherapy in Patients With Hemoglobinopathies
The purpose of this study is to determine if treatment with reduced-dose busulfex, fludarabine and alemtuzumab (CAMPATH) followed by sten cell infusion will allow for donor stem cells to grow in patients with hemoglobinopathies bone marrow and restore circulating blood counts.
In addition the incidence and severity of side effects and of graft vs. host disease (GVHD) will be monitored.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- In order to undergo transplant procedure, patients will be admitted to the hospital for approximately 10-14 days.
- To prepare patient's bone marrow to accept donor stem cells, they will receive fludarabine and busulfex. Fludarabine will be given intravenously once daily for 4 days. Busulfex will be given once daily for the same 4 days.
- One day before patients receive busulfex and fludarabine, they will also be given alemtuzumab intravenously once daily for 5 days.
- Three days after the end of chemotherapy, patients will receive the infusion of donor stem cells.
- If patients have thalassemia, they will receive subcutaneous injections of filgrastim starting on day one after the donor stem cell transfusion and will continue receiving filgrastim every day until it appears that the donor stem cells have been accepted. If the patient has sickle cell disease, filgrastim will not be given,
- Additional drugs will be given to help prevent infection (i.e. antibiotics).
- After stem cell infusion patients will be examined and have blood tests weekly for 1 month. Bone marrow biopsies, and blood work will also be performed 1 month, 3 months, 6 months and 1 year after stem cell infusion.
- Patients will be on the study for about 12 months. After study is completed progress will be monitored on an annual basis.
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute-Emory University
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71130
- Feist-Weiller Cancer Center-LSU
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02115
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02115
- Massachusetts General Hospital
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with sickle cell disease should have one or more of the following: acute chest syndrome requiring hospitalization; nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours; recurrent caso-occlusive pain or recurrent priapism; sickle neuropathy; bilateral proliferative retinopathy and major visual impairment of at least one eye; osteonecrosis of multiple joints; transfusion dependence; vaso-occlusive.
- Patients with thalassemia should have one or more of the following: transfusion dependence; iron overload; presence of 2 or more alloantibodies against red cell antigens.
Exclusion Criteria:
- Pregnancy
- Acute hepatitis
- Cardiac ejection fraction < 30%
- Severe renal impairment
- Severe residual functional neurologic impairment
- Evidence of HIV infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy.
Time Frame: 3 years
|
Outcome was measured by ANC >500 for three consecutive days prior to day 30 after PBSC infusion, >25% of hematopoietic cells are donor derived as determined by molecular chimerism assays or cytogenetic methods prior to day 45 after PBSC infusion and >25% of hematopoietic cells are donor derived as determined by molecular chimerism assays or cytogenetic methods after day 180 after PBSC infusion.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Solid Organ Toxicity Related to the Conditioning Regimen.
Time Frame: 3 years
|
Outcome was measured by the assessment of organ toxicity related to Busulfex, fludarabine and alemtuzumab.
|
3 years
|
The Incidence of Grade II-IV Acute Graft vs. Host Disease.
Time Frame: 3 years
|
Outcome was measured by incidence and severity of acute and chronic GVHD following donor stem cell infusion.
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Catherine J. Wu, MD, Dana-Farber Cancer Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2004
Primary Completion (Actual)
March 1, 2008
Study Completion (Actual)
July 1, 2009
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
July 30, 2013
Last Update Submitted That Met QC Criteria
July 24, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Anemia, Sickle Cell
- Thalassemia
- Hemoglobinopathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Fludarabine
- Busulfan
- Alemtuzumab
Other Study ID Numbers
- 03-338
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Busulfex
-
New York Medical CollegeRecruitingSinusoidal Obstruction Syndrome | Veno-occlusive DiseaseUnited States
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsTerminatedLeukemia, Myelocytic, AcuteUnited States
-
Ganzhou Hemay Pharmaceutical Co., LtdNot yet recruiting
-
Wuhan Union Hospital, ChinaRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia, Adult | Myelodysplastic Syndrome(MDS)China
-
Guido TricotOtsuka Pharmaceutical Development & Commercialization, Inc.TerminatedMultiple Myeloma
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawnRefractory Brain Tumors
-
Keimyung University Dongsan Medical CenterOtsuka Pharmaceutical Co., Ltd.RecruitingLymphoma, Extranodal NK-T-Cell | T-cell Non-Hodgkin LymphomaKorea, Republic of
-
M.D. Anderson Cancer CenterCompletedLymphoma | Multiple MyelomaUnited States
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompleted
-
Chonnam National University HospitalKorea Otsuka Pharmaceutical Co., Ltd.Unknown